Hostname: page-component-6766d58669-kl59c Total loading time: 0 Render date: 2026-05-16T09:32:04.182Z Has data issue: false hasContentIssue false

Measuring the benefits of treatment for psychosis: validity andresponsiveness of the EQ–5D

Published online by Cambridge University Press:  02 January 2018

Garry R. Barton*
Affiliation:
School of Medicine, Health Policy and Practice, University of East Anglia, Norwich
Jo Hodgekins
Affiliation:
School of Medicine, Health Policy and Practice, University of East Anglia, Norwich
Miranda Mugford
Affiliation:
School of Medicine, Health Policy and Practice, University of East Anglia, Norwich
Peter B. Jones
Affiliation:
CAMEO, Cambridgeshire and Peterborough Mental Health Partnership NHS Trust, and Department of Psychiatry, University of Cambridge
Tim Croudace
Affiliation:
Department of Psychiatry, University of Cambridge
David Fowler
Affiliation:
School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK
*
Dr Garry Barton, Health Economics Group, School of Medicine,Health Policy and Practice, University of East Anglia, Norwich NR4 7TJ, UK.Email: g.barton@uea.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

Background

The UK National Institute for Health and Clinical Excellence (NICE) has recommended that cost-effectiveness analysis includes the EQ–5D; however, this is often not implemented in the area of mental health.

Aims

To assess the appropriateness of using the EQ–5D to measure improvements in mental health.

Method

Seventy-seven participants with psychosis were rated according to the EQ–5D and seven measures of mental health at both pre- and post-intervention. To assess construct validity we compared the (pre-intervention) mean EQ–5D scores for those with milder and more severe scores, according to each of the seven measures. To assess responsiveness we estimated the mean EQ–5D change score for those who improved (post-intervention), according to each of the measures.

Results

The mean EQ–5D score was more favourable for both those with milder scores (mean difference: 0.044 to 0.301) and for those who improved post-intervention (mean change: 0.029 to 0.117).

Conclusions

This suggests the EQ–5D should be considered for use in future cost-effectiveness studies in the area of mental health.

Information

Type
Papers
Copyright
Copyright © Royal College of Psychiatrists, 2009 
Figure 0

Table 1 Mean scores at both baseline and 9 months post-intervention, and the change in score for each of the seven measures of mental health and the EQ-5D

Figure 1

Table 2 Baseline mean EQ–5D scores for those with milder and more severe scores and the mean difference between these two groups

Figure 2

Table 3 Baseline proportion who reported having a problem on each of the five dimensions of the EQ–5D for those with milder and more severe scores

Figure 3

Table 4 Baseline levels of correlations between each of the seven measures of mental health and the EQ–5D according to the Spearman rank test

Figure 4

Table 5 Mean change in EQ–5D scores for those whose scores improved, or did not improve, post-intervention and the mean difference between these two groups

Figure 5

Table 6 Change in the proportion who reported having no problems on each of the five dimensions of the EQ–5D (9-month compared with baseline assessment) for those whose scores improved, and did not improve, post-intervention

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.